Welcome to our dedicated page for ANGN news (Ticker: angn), a resource for investors and traders seeking the latest updates and insights on ANGN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ANGN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ANGN's position in the market.
Angion Biomedica Corp. (NASDAQ:ANGN) announced that Cowen and Company and Stifel, Nicolaus & Company, the lead managers of its recent public offering, agreed to partially waive a lock-up on approximately 100,267 common shares. These shares will be sold to meet tax obligations tied to the vesting of employee stock awards. This waiver takes effect on March 23, 2021, allowing the sale of shares thereafter. The sale is specifically for compliance with government withholding obligations under Angion’s employee equity incentive plans.
Angion Biomedica Corp. (NASDAQ:ANGN) announced that its management team will present at three upcoming virtual investor conferences in March 2021. Dr. Jay Venkatesan, President and CEO, will also participate in a kidney diseases panel at the Cowen 41st Annual Health Care Conference. The events include the Cowen Conference on March 3, HC Wainwright Conference on March 9, and Oppenheimer Conference on March 18. Webcasts will be available on Angion’s website for 30 days post-event.
Angion Biomedica Corp. (NASDAQ:ANGN) has successfully closed its initial public offering (IPO) and concurrent private placement, raising $117 million in gross proceeds. The IPO involved 5,750,000 shares priced at $16.00 each, including an extra 750,000 shares purchased by underwriters. Additionally, a private placement of 1,562,500 shares was completed with Vifor International, totaling $25 million. The shares are subject to a 180-day lock-up period. Angion's stock is now listed on the Nasdaq Global Select Market under the ticker symbol 'ANGN'.
Angion Biomedica Corp. (NASDAQ:ANGN) has announced the pricing of its initial public offering (IPO) on February 4, 2021, offering 5,000,000 shares at $16.00 each, aiming for gross proceeds of $80 million. The shares will trade on the Nasdaq Global Select Market starting February 5, 2021. Additionally, Angion will sell 1,562,500 shares in a concurrent private placement at the same price to existing stockholder Vifor International, Ltd. Both offerings are set to close on February 9, 2021, pending customary conditions.